Clinical trial
Safety of TG100-115 for Heart Attack Treated With Angioplasty
NCT00103350 · TargeGen, Industry · Completed
Key facts
| NCT number | NCT00103350 |
|---|---|
| Title | Safety of TG100-115 for Heart Attack Treated With Angioplasty |
| Official title | A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Prospective Study to Evaluate the Safety and Potential Efficacy of Single, Increasing Doses of TG100-115 in Subjects Undergoing Percutaneous Coronary Intervention for Acute Anterior ST Elevation Myocardial Infarction |
| Lead sponsor | TargeGen, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myocardial Infarction |
| Intervention type | Drug |
| Interventions | TG100-115 |
| Enrollment | 100 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Feb 8, 2005 |
| Last update posted | May 20, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: